We demonstrated that IL-17A was elevated in HFD-treated small intestine, and the neutralization of IL-17A improved the indomethacin-induced damage, intestinal permeability, and characteristics of endotoxemia. Here, IL17A is linked to serum lipopolysaccharide activity.